Rezolute, Inc. (RZLT) stock
RZLTNasdaqPharmaceutical PreparationsFiscal year ends June 30
$4.01+0.43 (+12.15%)
Close on Nov 17, 2026Market cap $388.34MP/E –Yield –
Rezolute EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Rezolute's EPS for the twelve months ending Sep 30, 2026 was -$0.76. For fiscal 2026 it was -$0.75. The highest annual figure on record is -$0.75 in fiscal 2026.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$0.75 | – |
| FY2025 | Jun 30, 2025 | -$0.98 | – |
| FY2024 | Jun 30, 2024 | -$1.33 | – |
| FY2023 | Jun 30, 2023 | -$1.01 | – |
| FY2022 | Jun 30, 2022 | -$2.32 | – |
| FY2021 | Jun 30, 2021 | -$2.72 | – |
| FY2020 | Jun 30, 2020 | -$3.54 | – |
| FY2019 | Jun 30, 2019 | -$18.41 | – |
| FY2018 | Jun 30, 2018 | -$27.00 | – |
| FY2017 | Jun 30, 2017 | -$28.50 | – |
| FY2016 | Jun 30, 2016 | -$42.00 | – |
| FY2015 | Jun 30, 2015 | -$27.00 | – |
| FY2014 | Jun 30, 2014 | -$52.00 | – |
| FY2011 | Dec 31, 2011 | -$1.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | -$0.18 | – |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -$0.20 | – |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -$0.16 | – |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -$0.22 | – |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | -$0.18 | – |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -$0.26 | – |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | -$0.27 | – |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | -$0.22 | – |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | -$0.22 | – |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -$0.44 | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -$0.34 | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -$0.27 | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -$0.28 | – |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -$0.25 | – |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -$0.30 | – |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -$0.26 | – |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -$0.19 | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -$0.26 | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -$0.65 | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -$0.80 | – |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -$0.92 | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$0.78 | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$0.44 | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$0.88 | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$0.62 | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$0.86 | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$1.14 | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$0.94 | – |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -$4.50 | – |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -$5.50 | – |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -$6.50 | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -$6.65 | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -$10.50 | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -$6.00 | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -$5.50 | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$18.76 | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$7.50 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?